Showing results (41-50 of 259) with videos related to
Sort By:
Pageof 26
Blood|January 11, 2024
How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemiaSteven P Treon, Shayna Sarosiek, Jorge J CastilloExpert Opinion on Drug Safety|March 1, 2021
Reducing treatment toxicity in Waldenström macroglobulinemiaShayna Sarosiek, Steven P Treon, Jorge J CastilloCurrent Treatment Options in Oncology|August 24, 2021
How to Sequence Therapies in Waldenström MacroglobulinemiaShayna Sarosiek, Steven P Treon, Jorge J CastilloClinical Lymphoma|March 30, 2005
CHOP plus rituximab therapy in Waldenstrom's macroglobulinemiaSteven P Treon, Zachary Hunter, Andrew R BarnaganHematology. American Society of Hematology. Education Program|November 25, 2004
Amyloidosis and Waldenström's macroglobulinemiaMorie A Gertz, Giampaolo Merlini, Steven P TreonAmerican Journal of Hematology|March 7, 2026
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing ImplicationsAlberto Guijosa, Nickolas Tsakamaklis, Margaret Kobs, et al.Blood|January 12, 2011
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemiaSandra Grass, Klaus-Dieter Preuss, Alexandra Wikowicz, et al.The Oncologist|July 31, 2016
Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based AnalysisAdam J Olszewski, Steven P Treon, Jorge J CastilloCancer Treatment and Research|February 7, 2015
Biology, prognosis, and therapy of Waldenström MacroglobulinemiaJorge J Castillo, Irene M Ghobrial, Steven P TreonCancer Journal (Sudbury, Mass.)|February 4, 2016
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative DisordersJorge J Castillo, Steven P Treon, Matthew S DavidsPageof 26